When will the full integration for R3 Reporting to Chinese Health Authorities be fully integrated with Argus? In Particular C.1.CN.1 E2B (R3) New Elements By Regional Requirements
(Doc ID 2626351.1)
Last updated on JANUARY 13, 2020
Applies to:Oracle Argus Interchange - Version 8.1.2 and later
Information in this document applies to any platform.
When will the full integration for R3 Reporting to Chinese Health Authorities be fully integrated with Argus?
CDE (Center For Drug Evaluation, NMPA) http://www.cde.org.cn/ - this is for Clinical Trial cases.
CDR (National Center for ADR Monitoring, China /Center for Drug Re-evaluation, NMPA) http://www.cdr-adr.org.cn/- this is for Post-Marketed cases.
C.1.CN.1 / Report Source
5=Literature (Full literature needed)
6=Study (ADR originated from authorization studies)
7=Program (ADR originated from marketing programs),
Currently the following steps allow customers to customize ICH based R3 profile in Argus Safety version AS 8.1+ for CFDA submissions to be accepted
Creating ICH E2B R3 profile for submitting serious, unexpected ADRS of clinical trial origin to CFDA (Chinese Health Authority). (Doc ID 2393471.1)
For future full integration we also have the below enhancements logged:
NEED ARGUS SAFETY TO SUPPORT CHINESE CHARACTERS(Bug 22472413)
Does Argus comply with Chinese PV requirements(Bug 19283335)
Oracle Consulting also have a customized Argus Chinese user interface available today on version 8.1.2+.
This is targeted for China local companies as it is truly English and Chinese and replaces Japanese.
This can be provided as part of a services engagement. (Refer Note 2457599.1)
To view full details, sign in with your My Oracle Support account.
Don't have a My Oracle Support account? Click to get started!
In this Document